Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Why Acadia Pharmaceuticals Stock Is Crashing Today
12:07pm, Tuesday, 21'st Jun 2022
An FDA advisory committee voted against recommending approval for pimavanserin in treating Alzheimer's disease psychosis.
Biotech Stock Plummets After FDA Snub
10:30am, Tuesday, 21'st Jun 2022
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock is one of the worst stocks on the Nasdaq today, down 35.6% to trade at $12.56 at last check.
Why Acadia Pharma Shares Are Plunging Today
08:34am, Tuesday, 21'st Jun 2022
A panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis.
FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid
03:27pm, Monday, 20'th Jun 2022 Zacks Investment Research
An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.
FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid
01:13pm, Monday, 20'th Jun 2022
An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.
Acadia Pharmaceuticals Inc. ACAD, +3.94% said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a t
HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate
03:46pm, Thursday, 16'th Jun 2022
HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected. It reiterates the stock with a Buy rating and a price target of $36.00.
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA
02:42pm, Thursday, 16'th Jun 2022 Zacks Investment Research
The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.
Acadia (ACAD) Surges 15.5%: Is This an Indication of Further Gains?
12:41pm, Thursday, 16'th Jun 2022 Zacks Investment Research
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA
12:20pm, Thursday, 16'th Jun 2022
The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.
Acadia (ACAD) Surges 15.5%: Is This an Indication of Further Gains?
10:50am, Thursday, 16'th Jun 2022
Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Why Acadia Pharmaceuticals Spiked Today
05:07pm, Wednesday, 15'th Jun 2022 The Motley Fool
Regulators might be warming to the company's candidate to treat Alzheimer's-associated psychosis.
Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?
03:07pm, Wednesday, 15'th Jun 2022
Ahead of Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag of opinions. The company's resubmit
Why Acadia Pharmaceuticals Spiked Today
01:07pm, Wednesday, 15'th Jun 2022
Regulators might be warming to the company's candidate to treat Alzheimer's-associated psychosis.
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2022 Update
04:49am, Monday, 06'th Jun 2022 Seeking Alpha
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The top 3 positions are T-Mobile US, Amazon.com, and General Electric, together, at ~16% of the portfolio.
